AMGN

AMGEN PRESENTS NEW RESEARCH ON OTEZLA® (APREMILAST) AT AAD 2024

Retrieved on: 
Saturday, March 9, 2024
Pustulosis palmaris et plantaris, Psoriasis, CPU socket, Aes, Headache, Diarrhea, Amgen, Pain, Pediatrics, DLQI, Skin, Nausea, Vomiting, Queen's University, AMGN, AAD, Safety, University, FRCPC, University of Alberta, PASI, Dermatology Life Quality Index, Patient, PST, Scalp, Ageing, Abdominal pain, Poster, American Academy, Pharmaceutical industry

THOUSAND OAKS, Calif., March 9, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new, 52-week results from the Phase 3 SPROUT study examining the use of Otezla® (apremilast) in children and adolescents aged 6 to 17 years with moderate to severe plaque psoriasis. These data, along with findings from a Phase 3 late-breaking study on Otezla in palmoplantar pustulosis, will be presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting, March 8-12 in San Diego.                                     

Key Points: 
  • These data, along with findings from a Phase 3 late-breaking study on Otezla in palmoplantar pustulosis, will be presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting, March 8-12 in San Diego.
  • "These data reflect Amgen's commitment to exploring new ways to treat inflammatory skin disease," said Ponda Motsepe-Ditshego, vice president, Global Medical, at Amgen.
  • Continued Otezla use resulted in sustained improvements in psoriasis severity and skin involvement in patients for up to one year.
  • Findings will be presented as a late-breaking oral presentation on Saturday, March 9 at 9:20 a.m. PST.

AMGEN TO PRESENT AT THE 44TH ANNUAL TD COWEN HEALTH CARE CONFERENCE

Retrieved on: 
Thursday, February 29, 2024
AMGN, Internet, Calendar, Webcast, Conference

THOUSAND OAKS, Calif., Feb. 29, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 44th Annual TD Cowen Health Care Conference at 9:10 a.m.

Key Points: 
  • THOUSAND OAKS, Calif., Feb. 29, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 44th Annual TD Cowen Health Care Conference at 9:10 a.m.
  • Peter Griffith, executive vice president and chief financial officer at Amgen, and Paul Burton, senior vice president and chief medical officer at Amgen, will present at the conference.
  • The webcast will be archived and available for replay for at least 90 days after the event.
  • To provide further context, information and detail around our activities with respect to our obesity program, Amgen has established a website called "Amgen Perspectives in Obesity".

AMGEN OPENS STATE-OF-THE-ART BIOMANUFACTURING SITE IN CENTRAL OHIO

Retrieved on: 
Monday, February 26, 2024
Amgen, AMGN, Disease, Made, Columbus State Community College, Carbon, Partnership

"Our new facility, known as Amgen Ohio, was designed with the latest innovation and technology to deliver safe, reliable medicines for 'every patient, every time,'" said Robert A. Bradway, chairman and chief executive officer at Amgen.

Key Points: 
  • "Our new facility, known as Amgen Ohio, was designed with the latest innovation and technology to deliver safe, reliable medicines for 'every patient, every time,'" said Robert A. Bradway, chairman and chief executive officer at Amgen.
  • "As part of Amgen's global biomanufacturing network, Amgen Ohio will play an important role in helping us address serious disease around the world with our innovative biomedicines."
  • "Winning this project for Ohio creates 400 high-paying jobs and a $40 million annual payroll, supporting families and further growing the Ohio economy."
  • In partnership with Columbus State Community College, Amgen is hosting an inaugural 18-month manufacturing apprenticeship at the site.

AMGEN TO HOST CONFERENCE CALL ON RARE DISEASE

Retrieved on: 
Monday, February 19, 2024
Rare disease, AMGN, Growth, Internet, Research and development, Calendar, Development, Webcast

THOUSAND OAKS, Calif., Feb. 19, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcasted call at 1:00 p.m. PT on Thursday, February 22, 2024 to discuss Rare Disease, its newly added fourth pillar of growth, and provide insights on its rare disease strategy and opportunities, including marketed products and pipeline.

Key Points: 
  • THOUSAND OAKS, Calif., Feb. 19, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcasted call at 1:00 p.m. PT on Thursday, February 22, 2024 to discuss Rare Disease, its newly added fourth pillar of growth, and provide insights on its rare disease strategy and opportunities, including marketed products and pipeline.
  • Murdo Gordon, executive vice president of Global Commercial Operations at Amgen, Jay Bradner, executive vice president of Research and Development and chief scientific officer at Amgen, Vikram Karnani, executive vice president of Global Commercial Operations and Medical Affairs (Rare Disease) at Amgen, and Paul Burton, senior vice president and chief medical officer at Amgen, will participate in the conference call.
  • The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.
  • Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar.

AMGEN TO PRESENT AT THE 34TH ANNUAL OPPENHEIMER HEALTHCARE LIFE SCIENCES CONFERENCE

Retrieved on: 
Friday, February 9, 2024
Internet, Development, Research and development, AMGN, Conference, Global marketing, Access, Webcast, Calendar

THOUSAND OAKS, Calif., Feb. 9, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 34th Annual Oppenheimer Healthcare Life Sciences Conference at 12:00 p.m.

Key Points: 
  • THOUSAND OAKS, Calif., Feb. 9, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 34th Annual Oppenheimer Healthcare Life Sciences Conference at 12:00 p.m.
  • Jay Bradner, executive vice president of Research and Development and chief scientific officer at Amgen, Murdo Gordon, executive vice president of Global Commerical Operations at Amgen, and Susan Sweeney, senior vice president of Global Marketing, Access and Capabilities at Amgen, will present at the conference.
  • Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar.
  • The webcast will be archived and available for replay for at least 90 days after the event.

AMGEN ANNOUNCES WEBCAST OF 2023 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS

Retrieved on: 
Thursday, February 1, 2024
Internet, Calendar, Webcast, AMGN, Broadcasting

THOUSAND OAKS, Calif., Feb. 1, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2023 financial results on Tuesday, February 6, 2024, after the close of the U.S. financial markets.

Key Points: 
  • THOUSAND OAKS, Calif., Feb. 1, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2023 financial results on Tuesday, February 6, 2024, after the close of the U.S. financial markets.
  • The announcement will be followed by a conference call with the investment community at 4:30 p.m.
  • Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team.
  • Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar.

deCODE genetics: A sequence variant that increases risk of pregnancy loss

Retrieved on: 
Monday, January 29, 2024
Woman, Synaptonemal complex, Genetic distance, Biology, Genome-wide association study, Genetics, Meiosis, Risk, Pregnancy, Chromosome, Genome, AMGN

Over 114 thousand women from Iceland, Denmark, the UK, USA, and Finland who have experienced pregnancy loss participated in a genome-wide association study, testing 50 million sequence variants.

Key Points: 
  • Over 114 thousand women from Iceland, Denmark, the UK, USA, and Finland who have experienced pregnancy loss participated in a genome-wide association study, testing 50 million sequence variants.
  • A low-frequency missense variant in the SYCE2 gene was found to increase the risk of pregnancy loss by 22%.
  • The association with pregnancy loss does not account for embryos lost in early gestation before pregnancy has been detected so the effect of the variant on pregnancy success may be underestimated.
  • The findings reported in this study demonstrate that a variant with a substantial effect on recombinations can be maintained in the population despite increasing the risk of pregnancy loss.

deCODE genetics: A sequence variant that increases risk of pregnancy loss

Retrieved on: 
Monday, January 29, 2024
Woman, Synaptonemal complex, Genetic distance, Biology, Genome-wide association study, Genetics, Meiosis, Risk, Pregnancy, Chromosome, Genome, AMGN

Over 114 thousand women from Iceland, Denmark, the UK, USA, and Finland who have experienced pregnancy loss participated in a genome-wide association study, testing 50 million sequence variants.

Key Points: 
  • Over 114 thousand women from Iceland, Denmark, the UK, USA, and Finland who have experienced pregnancy loss participated in a genome-wide association study, testing 50 million sequence variants.
  • A low-frequency missense variant in the SYCE2 gene was found to increase the risk of pregnancy loss by 22%.
  • The association with pregnancy loss does not account for embryos lost in early gestation before pregnancy has been detected so the effect of the variant on pregnancy success may be underestimated.
  • The findings reported in this study demonstrate that a variant with a substantial effect on recombinations can be maintained in the population despite increasing the risk of pregnancy loss.

Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030

Retrieved on: 
Tuesday, January 9, 2024
Pancreatic cancer, Research, Biology, Prostate cancer, Cancer, Cytokine release syndrome, CRS, AML, Population Reference Bureau, Audit committee, AMGN, NK, Neoplasm, ADC, Acute myeloid leukemia, Paracetamol, PMR, NKG2D, NSCLC, Disease, Safety, Conditional sentence, Brain, Lung cancer, Breast, PALM, Cytarabine, Senior, Prevalence, Genetics, Nonsteroidal anti-inflammatory drug, Drug discovery, Graft-versus-host disease, Ruxolitinib, TSX, Therapy, Kidney cancer, Ageing, Patient, Stomach, Complete Response Letter, Fentanyl, Breast cancer, Novartis, Society, Eli Lilly, News, Food, Cancer pain, Johnson & Johnson, Morphine, FDA, Ovarian cancer, New Drug Application, ASH, ONC, Pharmaceutical industry

Cancer is a non-treatable chronic disease that has posed a challenge to the medical fraternity for decades.

Key Points: 
  • Cancer is a non-treatable chronic disease that has posed a challenge to the medical fraternity for decades.
  • The entire medical research fraternity has prioritized cancer research in order to find new ways of treatment and analysis.
  • According to Nova one advisor, the global Oncology Cancer Drugs market was valued at USD 147.2 billion in 2021 and it is expected to hit around USD 289.2 billion by 2030 with a CAGR of 8.4% during the forecast period 2022 to 2030.
  • The article continued: “Drugs such as morphine, fentanyl, acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs), and others are used extensively in treating cancer pain in patients with lung cancer, bone cancer, and other types of cancer.

GLP-1: Beyond Diabetes, a Blockbuster Horizon Beckons

Retrieved on: 
Wednesday, January 10, 2024
Obesity, Bone density, Crohn's disease, Research, Addiction, Weight loss, History, Medicine, Amputation, Cancer, Autoimmune disease, Risk, WW International, Diarrhea, DSM-IV codes, Absorption, Liver disease, AMGN, LLY, Editorial, International, Diabetes, Amgen, GIP, Therapy, Novo Nordisk, Kidney disease, Eli Lilly and Company, Safety, Disease, Splenic infarction, Inflammation, Facial muscles, Brain, Vomiting, WW, Thought, Injection, LEXX, Weapon, Chronic kidney disease, OTCQX, GIPR, Pharmacokinetics, Patient, T2D, Nausea, Health, Paratriathlon, Partnership, SNAC, Insulin, Food, Stroke, Clinical trial, Overweight, Philosopher's stone, Ageing, Pharmaceutical industry

NEW YORK, Jan. 10, 2024 /PRNewswire/ -- On Sept. 20, 2019, history was made when the U.S. Food and Drug Administration approved Rybelsus as the first oral glucagon-like peptide-1 (GLP-1) agonist for type 2 diabetes (T2D). However, it wasn't just a milestone for T2D management. It was a turning point in medicine, opening the floodgates to a universe of potential therapeutic applications for this remarkable molecule. While undeniably transformative for diabetes and weight loss, GLP-1's reach now extends far beyond, likely surpassing even the wildest dreams of its creators. From Alzheimer's and Parkinson's to drug addiction, clinical trials are painting a stunning picture of GLP-1's versatility. And it doesn't stop there. Strong evidence points to opportunities in heart disease, chronic kidney disease and a plethora of other conditions. The newfound applications of this super-drug re-enforce the significant potential for Lexaria Bioscience Corp. (NASDAQ: LEXX) (Profile), with its powerful DehydraTECH(TM) drug-delivery formulation and processing technology that improves both delivery and efficacy of GLP-1 for diabetes and potentially a host of other maladies. Lexaria joins other companies, including Amgen Inc. (NASDAQ: AMGN), Eli Lilly and Company (NYSE: LLY), Roche (OTCQX: RHHBY) and WW International Inc. (NASDAQ: WW), that are committed to providing powerhouse solutions in the fields of diabetes, weight loss and more.

Key Points: 
  • GLP-1 agonists are among the hottest drugs in healthcare, with uses targeting multibillion-dollar diabetes and obesity markets and much more.
  • Lexaria Bioscience has developed DehydraTECH drug-delivery platform, which is being shown to improve pharmacokinetics of orally administered drugs.
  • Lexaria issued final data from the pilot study and is planning for multiple human and animal studies early in 2024.
  • Uncontrolled blood sugar dramatically increases the risk of devastating comorbidities, including kidney disease, vision loss, amputations, heart attacks, strokes and early death.